RenovoR announced that, in light of its recent successful fundraising activity, it has received written confirmation from The Nasdaq Stock Market that the Company has regained compliance with the $2.5M minimum stockholders’ equity requirement in Nasdaq Listing Rule 5550 b1 . As a result, the Company’s previously announced hearing before a Nasdaq Hearings Panel on this matter is no longer required and has been cancelled. Further, the Company will not require any ongoing Nasdaq Hearings Panel monitor.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT:
- RenovoRx price target lowered to $3.50 from $4 at Alliance Global Partners
- RenovoRx Secures $11.1M Through Equity and Warrants Offering
- RenovoRx to present initial interim analysis of Phase III TIGeR-PaC trial
- RNXT Earnings this Week: How Will it Perform?
- RenovoRx promotes Leesa Gentry to chief clinical officer